Beyond GLP-1: The Next Wave of Peptide Innovation Could Unlock Billions in Biotech Growth
Key Highlights
- ➤Peptide therapeutics market projected from $140.9B in 2025 to $294.6B by 2033
- ➤Precision Peptide gains TikTok Shop approval, reaching 53 million U.S. buyers
- ➤Vesalius secures US$6.5 million financing led by Harvey Spevak
- ➤Vector Science introduces investigational peptide-matrix dissolving microneedle technology
- ➤Lilly-Hims agreement offers Foundayo from $149/month and Zepbound from $299/month
Expert Statements
Pratap Sandhu, CEO of The Precision Peptide Company
“Winning approval for a TikTok Shop at the same time the platform is tightening its rules on peptides is a real milestone for us. TikTok holds anyone in the peptide space to a high bar, and we built our range to meet it. Every product we bring to the platform is U.S.-made and backed by third-party testing. Our first product is live, and we will keep adding to the shop as each one clears review. This is a bigger step into social commerce for the Company, and we intend to build on it.”
Ilya Yuffa, Executive Vice President and President, Lilly USA and Global Customer Capabilities, Eli Lilly and Company
“At Lilly, we are always looking for new ways to help more people get the medicines they need, and that means meeting patients where they already are. Millions of people turn to Hims & Hers for their care, and through this agreement, those patients now have a simple, more direct way to get FDA-approved Lilly medicine at an affordable price if prescribed.”
NEW YORK, Nov. 19, 2026 (GLOBE NEWSWIRE) -- Peptides are becoming a bigger part of the pharmaceutical business, and the money flowing into this market is getting harder to ignore. GLP-1 treatments for diabetes and weight management have put peptide-based drugs in the spotlight, but the opportunity goes well beyond those products. Pharmaceutical companies are also pursuing peptide treatments for cancer, cardiovascular disease, metabolic disorders, rare diseases, and other conditions where existing therapies may fall short. Grand View Research estimates the global peptide therapeutics market was worth approximately $140.9 billion in 2025, with projections reaching $294.6 billion by 2033. That is more than $150 billion in potential market growth over eight years. Other research firms offer different estimates based on how they define the market, but the direction is clear: peptide-based medicines are becoming an increasingly important part of drug development, with major pharmaceutical companies looking to capitalize on growing demand. Those targeting Biotech and Wellness growth should watch these Companies poised to capitalize on Today’s Opportunities could include: The Precision Peptide Company Inc. (OTCQB: PNGAF) (CSE: BPC), Eli Lilly and Company (NYSE: LLY), Hims & Hers Health, Inc. (NYSE: HIMS), Vector Science and Therapeutics Corp. (TSXV: PAIN), Vesalius Longevity Labs Inc. (CSE: VLAB).
Get started
Create a free account to read the full story.
